PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel–Treated Advanced Triple-Negative Breast Cancer

BACKGROUND: In the phase III IMpassion130 study, atezolizumab plus nab-paclitaxel (A+nP) showed clinical benefit in advanced or metastatic triple-negative breast cancer patients who were programmed death-ligand 1 (PD-L1)+ (tumor-infiltrating immune cells [IC] ≥1%) using the SP142 immunohistochemistr...

Descripción completa

Detalles Bibliográficos
Autores principales: Rugo, Hope S, Loi, Sherene, Adams, Sylvia, Schmid, Peter, Schneeweiss, Andreas, Barrios, Carlos H, Iwata, Hiroji, Diéras, Véronique, Winer, Eric P, Kockx, Mark M, Peeters, Dieter, Chui, Stephen Y, Lin, Jennifer C, Nguyen-Duc, Anh, Viale, Giuseppe, Molinero, Luciana, Emens, Leisha A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8634452/
https://www.ncbi.nlm.nih.gov/pubmed/34097070
http://dx.doi.org/10.1093/jnci/djab108

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8634452/
https://www.ncbi.nlm.nih.gov/pubmed/34097070
http://dx.doi.org/10.1093/jnci/djab108

Ejemplares similares